Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

This study has been completed.
Information provided by (Responsible Party):
BioCryst Pharmaceuticals Identifier:
First received: December 20, 2010
Last updated: October 28, 2013
Last verified: October 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 4, 2013